Society guideline links: Scleroderma in children

Introduction — 

This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Morphea (localized scleroderma)" and "Society guideline links: Systemic sclerosis (scleroderma)".)

International

●Best clinical practice in the treatment of juvenile systemic sclerosis – Expert panel guidance: The result of the International Hamburg Consensus Meeting December 2022 (published 2024)

●Consensus-based recommendations for the management of juvenile localised scleroderma (2019)

United States

●Childhood Arthritis and Rheumatology Research Alliance (CARRA): Development of consensus treatment plans for juvenile localized scleroderma – A roadmap toward comparative effectiveness studies in juvenile localized scleroderma (2012)

Europe

●Single Hub and Access point for paediatric Rheumatology in Europe (SHARE): Consensus-based recommendations for the management of juvenile systemic sclerosis (2021)

●European Dermatology Forum (EDF): S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, part 1 – Localized scleroderma, systemic sclerosis and overlap syndromes (2017)